JP2004506438A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004506438A5 JP2004506438A5 JP2002520848A JP2002520848A JP2004506438A5 JP 2004506438 A5 JP2004506438 A5 JP 2004506438A5 JP 2002520848 A JP2002520848 A JP 2002520848A JP 2002520848 A JP2002520848 A JP 2002520848A JP 2004506438 A5 JP2004506438 A5 JP 2004506438A5
- Authority
- JP
- Japan
- Prior art keywords
- hmgcb
- cells
- class
- formulation
- mannose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 description 225
- 210000004027 cell Anatomy 0.000 description 81
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 63
- 239000000203 mixture Substances 0.000 description 41
- 102000004547 Glucosylceramidase Human genes 0.000 description 39
- 108010017544 Glucosylceramidase Proteins 0.000 description 39
- 239000002603 mannosidase inhibitor Substances 0.000 description 39
- 238000009472 formulation Methods 0.000 description 38
- 239000002243 precursor Substances 0.000 description 24
- 102000001696 Mannosidases Human genes 0.000 description 23
- 108010054377 Mannosidases Proteins 0.000 description 23
- 150000002482 oligosaccharides Chemical class 0.000 description 23
- 229920001542 oligosaccharide Polymers 0.000 description 20
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 17
- 108091026890 Coding region Proteins 0.000 description 11
- 238000005277 cation exchange chromatography Methods 0.000 description 11
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 10
- 238000005571 anion exchange chromatography Methods 0.000 description 10
- 230000000692 anti-sense effect Effects 0.000 description 10
- 238000004255 ion exchange chromatography Methods 0.000 description 10
- 230000001105 regulatory effect Effects 0.000 description 10
- FXUAIOOAOAVCGD-FKSUSPILSA-N swainsonine Chemical group C1CC[C@H](O)[C@H]2[C@H](O)[C@H](O)CN21 FXUAIOOAOAVCGD-FKSUSPILSA-N 0.000 description 10
- 229960005566 swainsonine Drugs 0.000 description 10
- FXUAIOOAOAVCGD-UHFFFAOYSA-N swainsonine Natural products C1CCC(O)C2C(O)C(O)CN21 FXUAIOOAOAVCGD-UHFFFAOYSA-N 0.000 description 10
- 238000001542 size-exclusion chromatography Methods 0.000 description 9
- YINZYTTZHLPWBO-UHFFFAOYSA-N Kifunensine Natural products COC1C(O)C(O)C(O)C2NC(=O)C(=O)N12 YINZYTTZHLPWBO-UHFFFAOYSA-N 0.000 description 8
- 229920002684 Sepharose Polymers 0.000 description 8
- OIURYJWYVIAOCW-VFUOTHLCSA-N kifunensine Chemical compound OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H]2NC(=O)C(=O)N12 OIURYJWYVIAOCW-VFUOTHLCSA-N 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 7
- 229930184337 Mannostatin Natural products 0.000 description 6
- BLOFGONIVNXZME-YDMGZANHSA-N mannostatin A Chemical compound CS[C@@H]1[C@@H](N)[C@@H](O)[C@@H](O)[C@H]1O BLOFGONIVNXZME-YDMGZANHSA-N 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 150000007523 nucleic acids Chemical group 0.000 description 5
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 4
- 229920002271 DEAE-Sepharose Polymers 0.000 description 4
- 208000015872 Gaucher disease Diseases 0.000 description 4
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical group CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 4
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 4
- 239000012506 Sephacryl® Substances 0.000 description 4
- 239000012505 Superdex™ Substances 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- LXBIFEVIBLOUGU-KVTDHHQDSA-N (2r,3r,4r,5r)-2-(hydroxymethyl)piperidine-3,4,5-triol Chemical compound OC[C@H]1NC[C@@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-KVTDHHQDSA-N 0.000 description 3
- LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000001114 myogenic effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/641,471 US7138262B1 (en) | 2000-08-18 | 2000-08-18 | High mannose proteins and methods of making high mannose proteins |
| US09/641,471 | 2000-08-18 | ||
| PCT/US2001/025882 WO2002015927A1 (en) | 2000-08-18 | 2001-08-17 | High mannose proteins and methods of making high mannose proteins |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011173243A Division JP5683407B2 (ja) | 2000-08-18 | 2011-08-08 | 高マンノースタンパク質および高マンノースタンパク質の製造方法 |
| JP2011173242A Division JP5840890B2 (ja) | 2000-08-18 | 2011-08-08 | 高マンノースタンパク質および高マンノースタンパク質の製造方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004506438A JP2004506438A (ja) | 2004-03-04 |
| JP2004506438A5 true JP2004506438A5 (cg-RX-API-DMAC7.html) | 2008-10-09 |
| JP5008245B2 JP5008245B2 (ja) | 2012-08-22 |
Family
ID=24572532
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002520848A Expired - Lifetime JP5008245B2 (ja) | 2000-08-18 | 2001-08-17 | 高マンノースタンパク質および高マンノースタンパク質の製造方法 |
| JP2011173243A Expired - Fee Related JP5683407B2 (ja) | 2000-08-18 | 2011-08-08 | 高マンノースタンパク質および高マンノースタンパク質の製造方法 |
| JP2011173242A Expired - Fee Related JP5840890B2 (ja) | 2000-08-18 | 2011-08-08 | 高マンノースタンパク質および高マンノースタンパク質の製造方法 |
| JP2014209206A Pending JP2015015964A (ja) | 2000-08-18 | 2014-10-10 | 高マンノースタンパク質および高マンノースタンパク質の製造方法 |
| JP2016089304A Expired - Lifetime JP6659443B2 (ja) | 2000-08-18 | 2016-04-27 | 高マンノースタンパク質および高マンノースタンパク質の製造方法 |
| JP2018000449A Expired - Lifetime JP6626133B2 (ja) | 2000-08-18 | 2018-01-05 | 高マンノースタンパク質および高マンノースタンパク質の製造方法 |
| JP2018090467A Expired - Lifetime JP6681428B2 (ja) | 2000-08-18 | 2018-05-09 | 高マンノースタンパク質および高マンノースタンパク質の製造方法 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011173243A Expired - Fee Related JP5683407B2 (ja) | 2000-08-18 | 2011-08-08 | 高マンノースタンパク質および高マンノースタンパク質の製造方法 |
| JP2011173242A Expired - Fee Related JP5840890B2 (ja) | 2000-08-18 | 2011-08-08 | 高マンノースタンパク質および高マンノースタンパク質の製造方法 |
| JP2014209206A Pending JP2015015964A (ja) | 2000-08-18 | 2014-10-10 | 高マンノースタンパク質および高マンノースタンパク質の製造方法 |
| JP2016089304A Expired - Lifetime JP6659443B2 (ja) | 2000-08-18 | 2016-04-27 | 高マンノースタンパク質および高マンノースタンパク質の製造方法 |
| JP2018000449A Expired - Lifetime JP6626133B2 (ja) | 2000-08-18 | 2018-01-05 | 高マンノースタンパク質および高マンノースタンパク質の製造方法 |
| JP2018090467A Expired - Lifetime JP6681428B2 (ja) | 2000-08-18 | 2018-05-09 | 高マンノースタンパク質および高マンノースタンパク質の製造方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7138262B1 (cg-RX-API-DMAC7.html) |
| EP (3) | EP1309340B1 (cg-RX-API-DMAC7.html) |
| JP (7) | JP5008245B2 (cg-RX-API-DMAC7.html) |
| CN (4) | CN102559633A (cg-RX-API-DMAC7.html) |
| AU (1) | AU785460B2 (cg-RX-API-DMAC7.html) |
| CA (3) | CA2388041C (cg-RX-API-DMAC7.html) |
| HK (1) | HK1205183A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL149029A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA02003894A (cg-RX-API-DMAC7.html) |
| NZ (2) | NZ537128A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2002015927A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL155588A0 (en) * | 2003-04-27 | 2003-11-23 | Metabogal Ltd | Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby |
| US7138262B1 (en) * | 2000-08-18 | 2006-11-21 | Shire Human Genetic Therapies, Inc. | High mannose proteins and methods of making high mannose proteins |
| US7951557B2 (en) | 2003-04-27 | 2011-05-31 | Protalix Ltd. | Human lysosomal proteins from plant cell culture |
| US20050137223A1 (en) * | 2003-11-12 | 2005-06-23 | Amicus Therapeutics, Inc. | Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease |
| EP1866071A4 (en) * | 2005-03-03 | 2013-04-24 | Univ Indiana Res & Tech Corp | PERMETHYLATION OF OLIGOSACCHARIDES |
| CA2601797A1 (en) * | 2005-03-16 | 2006-09-21 | University Of Oxford | Mannose immunogens for hiv-1 |
| WO2006110277A1 (en) | 2005-04-11 | 2006-10-19 | Medarex, Inc. | Protein purification using hcic amd ion exchange chromatography |
| US8202523B2 (en) | 2005-09-22 | 2012-06-19 | ProSci, Inc. | Glycosylated polypeptides produced in yeast mutants and methods of use thereof |
| DK1945665T3 (da) * | 2005-10-21 | 2012-02-06 | Genzyme Corp | Antistof-baserede terapimidler med forhøjet ADCC-aktivitet |
| ES2391657T3 (es) | 2006-02-07 | 2012-11-28 | Shire Human Genetic Therapies, Inc. | Composiciones estabilizadas de proteínas que tienen un resto tiol libre |
| EP2102335B1 (en) * | 2007-01-04 | 2012-02-22 | Crucell Holland B.V. | Purification of factor xi |
| ES2660667T3 (es) | 2007-05-07 | 2018-03-23 | Protalix Ltd. | Biorreactor desechable a gran escala |
| AU2010281403B2 (en) | 2009-07-28 | 2016-03-10 | Takeda Pharmaceutical Company Limited | Compositions and methods for treating Gaucher disease |
| WO2011019620A1 (en) | 2009-08-10 | 2011-02-17 | Genentech, Inc. | Antibodies with enhanced adcc function |
| CA2773133A1 (en) | 2009-08-28 | 2011-03-03 | Edward H. Schuchman | Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency |
| CA2790786C (en) * | 2010-02-24 | 2019-09-24 | Zymenex A/S | Process for production and purification of recombinant lysosomal alpha-mannosidase |
| WO2012012461A2 (en) | 2010-07-19 | 2012-01-26 | Shire Human Genetic Therapies, Inc. | Mannose receptor c type 1 (mrc1) codon optimized cell line and uses thereof |
| CN103154243A (zh) | 2010-10-15 | 2013-06-12 | 日本化学研究株式会社 | 糖链的非还原末端为甘露糖残基的糖蛋白的制造方法 |
| SG10201605874TA (en) | 2011-04-22 | 2016-09-29 | Genzyme Corp | Modified acid alpha glucosidase with accelerated processing |
| WO2013055888A2 (en) | 2011-10-12 | 2013-04-18 | Synageva Biopharma Corp. | Recombinant human naglu protein and uses thereof |
| EP2606741B1 (en) * | 2011-12-23 | 2014-04-16 | Foodip Sarl | Glycoprotein enriched composition as a food and feed additive and/or as a therapeutic agent |
| WO2013130963A1 (en) | 2012-03-02 | 2013-09-06 | Shire Human Genetic Therapies, Inc. | Compositions and methods for treating type iii gaucher disease |
| CN102827212B (zh) * | 2012-07-25 | 2015-04-15 | 中国科学院海洋研究所 | 一种乙酰化壳三糖的制备方法 |
| TWI793159B (zh) * | 2013-10-23 | 2023-02-21 | 美商健臻公司 | 重組醣蛋白及其用途 |
| SI3063287T1 (sl) * | 2013-10-31 | 2025-06-30 | Amgen, Inc. | Uporaba monenzina za regulacijo glikozilacije rekombinantnih proteinov |
| AU2015323966A1 (en) | 2014-09-29 | 2017-03-16 | Alexion Pharmaceuticals, Inc. | Methods of treating mucopolysaccharidosis IIIB (MPSIIIB) |
| KR102803158B1 (ko) | 2015-12-02 | 2025-05-08 | 주식회사 에스티큐브앤컴퍼니 | Btn1a1에 면역특이적으로 결합하는 항체와 분자 및 그의 치료 용도 |
| CN108795871B (zh) * | 2017-04-28 | 2021-12-03 | 江南大学 | 用于生产糖蛋白的动物细胞株及方法、糖蛋白及其用途 |
| CN111051346A (zh) | 2017-05-31 | 2020-04-21 | 斯特库伯株式会社 | 使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法 |
| CN111148762A (zh) | 2017-05-31 | 2020-05-12 | 斯特库伯株式会社 | 免疫特异性结合至btn1a1的抗体和分子及其治疗性用途 |
| JP2020522562A (ja) | 2017-06-06 | 2020-07-30 | ストキューブ アンド シーオー., インコーポレイテッド | Btn1a1又はbtn1a1リガンドに結合する抗体及び分子を用いて癌を治療する方法 |
| CN108179160B (zh) * | 2018-01-29 | 2021-05-11 | 江南大学 | 一种植烷醇连接的高甘露糖型寡糖的制备方法 |
| CN108588127A (zh) * | 2018-04-11 | 2018-09-28 | 上海药明生物技术有限公司 | 一种表达高甘露糖糖型的葡萄糖脑苷脂酶的细胞株及其制备方法和应用 |
| CN113795575A (zh) * | 2019-02-04 | 2021-12-14 | 自由行疗法有限公司 | 多核苷酸 |
| CN119530200A (zh) * | 2024-11-28 | 2025-02-28 | 北海康成(苏州)生物制药有限公司 | 一种维拉苷酶β的纯化方法和药液 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5272066A (en) | 1986-03-07 | 1993-12-21 | Massachusetts Institute Of Technology | Synthetic method for enhancing glycoprotein stability |
| US4925796A (en) | 1986-03-07 | 1990-05-15 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
| WO1989005850A1 (en) * | 1987-12-23 | 1989-06-29 | The United States Of America, As Represented By Th | Cloned dna for synthesizing unique glucocerebrosidase |
| US5549892A (en) | 1988-12-23 | 1996-08-27 | Genzyme Corporation | Enhanced in vivo uptake of glucocerebrosidase |
| JPH03503721A (ja) | 1988-12-23 | 1991-08-22 | ジェンザイム コーポレイション | 酵素的に活性な組換えグルコセレブロシダーゼ |
| US5236838A (en) | 1988-12-23 | 1993-08-17 | Genzyme Corporation | Enzymatically active recombinant glucocerebrosidase |
| JP2893481B2 (ja) | 1988-12-23 | 1999-05-24 | ジェンザイム コーポレイション | 酵素的に活性な組換えグルコセレブロシダーゼ |
| US5401650A (en) | 1990-10-24 | 1995-03-28 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of biologically active α-galactosidase A |
| EP0568647B1 (en) | 1991-01-21 | 1996-09-11 | Genzyme Corporation | Production of enzymatically active glucocerebrosidase from recombinant cells |
| US5968502A (en) | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| US6270989B1 (en) * | 1991-11-05 | 2001-08-07 | Transkaryotic Therapies, Inc. | Protein production and delivery |
| US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| US5911983A (en) | 1992-06-26 | 1999-06-15 | University Of Pittsburgh | Gene therapy for Gaucher disease using retroviral vectors |
| CA2150956A1 (en) | 1992-12-10 | 1994-06-23 | Robert G. L. Shorr | Glycolipid enzyme-polymer conjugates |
| WO1994014837A1 (en) | 1992-12-21 | 1994-07-07 | Enzon, Inc. | Purification of proteinaceous material |
| JP3002113B2 (ja) | 1994-03-30 | 2000-01-24 | 寳酒造株式会社 | 糖質又は複合糖質の製造方法 |
| EP0675204B1 (en) | 1994-03-30 | 2001-05-30 | Takara Shuzo Co. Ltd. | Transglycosylating process for producing carbohydrates or glycoconjugates |
| US5670132A (en) | 1994-09-20 | 1997-09-23 | Immunomedics, Inc. | Modified radioantibody fragments for reduced renal uptake |
| EP0865499B1 (en) * | 1995-09-14 | 2009-03-18 | Virginia Tech Intellectual Properties, Inc. | Production of lysosomal enzymes in plant-based expression systems |
| WO1997032591A1 (en) | 1996-03-05 | 1997-09-12 | Orquest, Inc. | Method of promoting bone growth with hyaluronic acid and growth factors |
| US6177447B1 (en) * | 1996-07-15 | 2001-01-23 | Universiteit Van Amsterdam | Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors |
| NZ506214A (en) * | 1996-09-13 | 2002-11-26 | Transkaryotic Therapies Inc | Therapy for alpha-galactosidase A deficiency |
| EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| JPH10273500A (ja) | 1997-03-03 | 1998-10-13 | Noguchi Inst | 複合糖ペプチド及びその製造法 |
| JPH10306099A (ja) | 1997-03-04 | 1998-11-17 | Noguchi Inst | 新規複合糖ペプチドおよびその製法 |
| TW542721B (en) | 1997-08-06 | 2003-07-21 | Melaleuca Inc | Dietary supplements containing natural ingredients |
| DE69825288D1 (de) | 1997-08-07 | 2004-09-02 | Univ Utah | Prodrugs und konjugate von selenolenthaltenden verbindungen und ihre verwendung |
| US5939279A (en) * | 1997-09-18 | 1999-08-17 | The Board Of Trustees Of The University Of Arkansas | Inhibition of bacterial binding by high-mannose oligosaccharides |
| EP1041996A4 (en) | 1997-12-22 | 2003-05-14 | Human Genome Sciences Inc | KERATINOCYTE GROWTH FACTOR-2 FORMULATIONS |
| GB9802249D0 (en) | 1998-02-03 | 1998-04-01 | Ciba Geigy Ag | Organic compounds |
| GB9807464D0 (en) | 1998-04-07 | 1998-06-10 | Pharming Bv | Purification of human acid µ-glucosidase |
| EP0976838A1 (en) | 1998-05-06 | 2000-02-02 | Rhone-Poulenc Nutrition Animale | Enzymes mixture |
| JPH11318441A (ja) | 1998-05-14 | 1999-11-24 | Nagase & Co Ltd | 超耐熱耐酸性アミロプルラナーゼ |
| KR19990086271A (ko) | 1998-05-27 | 1999-12-15 | 손경식 | 면역세포의 신규한 엔도뉴클레아제 및 이를 사용한 면역보조제 |
| KR20010052499A (ko) | 1998-06-05 | 2001-06-25 | 아방티 파르마 소시에테 아노님 | 베타-시크리타제형 활성을 지닌 폴리펩타이드 |
| PT1137789E (pt) * | 1998-12-09 | 2010-10-21 | Phyton Holdings Llc | Um método para produzir glicoproteínas possuindo glicosilação de tipo humano |
| GB9909066D0 (en) | 1999-04-20 | 1999-06-16 | Oxford Glycosciences Uk Ltd | Therapies |
| EP1189599A2 (en) | 1999-06-11 | 2002-03-27 | Eli Lilly And Company | Pharmaceutical materials and methods for their preparation and use |
| JP2003505430A (ja) | 1999-07-26 | 2003-02-12 | ジー・ディー・サール・アンド・カンパニー | デオキシノジリマイシンの長鎖n−アルキル誘導体およびグルコセレブロシダーゼ酵素の糖脂質異常蓄積疾患の治療用の薬剤の製造のための使用 |
| US6770468B1 (en) | 1999-09-14 | 2004-08-03 | Genzyme Glycobiology Research Institute, Inc. | Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway |
| US6534300B1 (en) | 1999-09-14 | 2003-03-18 | Genzyme Glycobiology Research Institute, Inc. | Methods for producing highly phosphorylated lysosomal hydrolases |
| IL150314A0 (en) | 1999-12-30 | 2002-12-01 | Maxygen Aps | Improved lysosomal enzymes and lysosomal enzyme activators |
| US20040204379A1 (en) | 2000-06-19 | 2004-10-14 | Cheng Seng H. | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| US20020095135A1 (en) * | 2000-06-19 | 2002-07-18 | David Meeker | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| US7138262B1 (en) | 2000-08-18 | 2006-11-21 | Shire Human Genetic Therapies, Inc. | High mannose proteins and methods of making high mannose proteins |
| CN1156702C (zh) | 2001-07-11 | 2004-07-07 | 上海晶泰生物技术有限公司 | 采用标记链霉亲和素-生物素技术的蛋白质芯片 |
| US20040202666A1 (en) | 2003-01-24 | 2004-10-14 | Immunomedics, Inc. | Anti-cancer anthracycline drug-antibody conjugates |
| JP5589165B2 (ja) | 2003-01-31 | 2014-09-17 | マウント シナイ スクール オブ メディシン オブ ニューヨーク ユニバーシティー | タンパク質欠損性障害の治療のための併用療法 |
| US20060008415A1 (en) | 2004-06-25 | 2006-01-12 | Protein Design Labs, Inc. | Stable liquid and lyophilized formulation of proteins |
| NZ555308A (en) | 2004-12-22 | 2010-10-29 | Ambrx Inc | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
| WO2007019232A2 (en) | 2005-08-03 | 2007-02-15 | Immunogen, Inc. | Immunoconjugate formulations |
| ES2391657T3 (es) | 2006-02-07 | 2012-11-28 | Shire Human Genetic Therapies, Inc. | Composiciones estabilizadas de proteínas que tienen un resto tiol libre |
| ES2366059T3 (es) | 2006-03-17 | 2011-10-14 | Biomarin Pharmaceutical Inc. | Ensayos para la detección de anticuerpos anti-enzimas lisosómicas. |
| NZ572226A (en) | 2006-04-18 | 2011-05-27 | Ekr Therapeutics Inc | Pre-mixed, ready-to-use IV bolus compositions comprising nicardipine and methods of use |
| DK2040548T3 (da) | 2006-06-23 | 2012-08-13 | Amicus Therapeutics Inc | Fremgangsmåde til behandling af neurologiske forstyrrelser ved forøgelse af aktiviteten af beta-glucocerebrosidase |
| DK2041270T3 (da) | 2006-07-13 | 2014-01-27 | Wyeth Llc | Fremstilling af glycoproteiner |
| TWI489984B (zh) | 2006-08-04 | 2015-07-01 | Wyeth Corp | 用於非經腸道傳輸化合物之配方及其用途 |
| AU2010281403B2 (en) | 2009-07-28 | 2016-03-10 | Takeda Pharmaceutical Company Limited | Compositions and methods for treating Gaucher disease |
| US20130017169A1 (en) | 2010-03-02 | 2013-01-17 | Protalix Ltd. | Multimeric forms of therapeutic proteins and uses thereof |
| WO2012012461A2 (en) | 2010-07-19 | 2012-01-26 | Shire Human Genetic Therapies, Inc. | Mannose receptor c type 1 (mrc1) codon optimized cell line and uses thereof |
-
2000
- 2000-08-18 US US09/641,471 patent/US7138262B1/en not_active Expired - Lifetime
-
2001
- 2001-08-17 NZ NZ537128A patent/NZ537128A/en not_active IP Right Cessation
- 2001-08-17 EP EP01964176.0A patent/EP1309340B1/en not_active Expired - Lifetime
- 2001-08-17 EP EP14170682.0A patent/EP2805727A1/en not_active Withdrawn
- 2001-08-17 EP EP10182992.7A patent/EP2292256B1/en not_active Expired - Lifetime
- 2001-08-17 CA CA2388041A patent/CA2388041C/en not_active Expired - Lifetime
- 2001-08-17 MX MXPA02003894A patent/MXPA02003894A/es active IP Right Grant
- 2001-08-17 NZ NZ519014A patent/NZ519014A/en not_active IP Right Cessation
- 2001-08-17 IL IL14902901A patent/IL149029A0/xx active IP Right Grant
- 2001-08-17 CN CN201210019823XA patent/CN102559633A/zh active Pending
- 2001-08-17 CN CNB018028012A patent/CN100352499C/zh not_active Expired - Lifetime
- 2001-08-17 AU AU85061/01A patent/AU785460B2/en not_active Expired
- 2001-08-17 CN CN2007101051513A patent/CN101085345B/zh not_active Expired - Lifetime
- 2001-08-17 WO PCT/US2001/025882 patent/WO2002015927A1/en not_active Ceased
- 2001-08-17 JP JP2002520848A patent/JP5008245B2/ja not_active Expired - Lifetime
- 2001-08-17 CN CN201410418047.XA patent/CN104312995A/zh active Pending
- 2001-08-17 CA CA2767054A patent/CA2767054C/en not_active Expired - Lifetime
- 2001-08-17 CA CA2767473A patent/CA2767473C/en not_active Expired - Lifetime
-
2002
- 2002-04-08 IL IL149029A patent/IL149029A/en unknown
-
2006
- 2006-10-17 US US11/581,979 patent/US10041137B2/en not_active Expired - Fee Related
-
2011
- 2011-08-08 JP JP2011173243A patent/JP5683407B2/ja not_active Expired - Fee Related
- 2011-08-08 JP JP2011173242A patent/JP5840890B2/ja not_active Expired - Fee Related
-
2014
- 2014-10-10 JP JP2014209206A patent/JP2015015964A/ja active Pending
-
2015
- 2015-06-10 HK HK15105530.9A patent/HK1205183A1/xx unknown
-
2016
- 2016-04-27 JP JP2016089304A patent/JP6659443B2/ja not_active Expired - Lifetime
-
2018
- 2018-01-05 JP JP2018000449A patent/JP6626133B2/ja not_active Expired - Lifetime
- 2018-05-09 JP JP2018090467A patent/JP6681428B2/ja not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2388041A1 (en) | High mannose proteins and methods of making high mannose proteins | |
| Schwarz et al. | Inhibitors of trimming: new tools in glycoprotein research | |
| JP2015015964A5 (cg-RX-API-DMAC7.html) | ||
| UA53655C2 (uk) | Спосіб лікування ожиріння | |
| KR20000035992A (ko) | 폴리디티오카르바메이트 함유 거대분자 및 치료 및 진단을 위한 | |
| JPH01254623A (ja) | スフインゴ糖脂質代謝の阻害剤を有効成分として含有する癌治療薬 | |
| MXPA01010707A (es) | Combinacion de inhibidores de sintesis de glucosilceramida y enzima degradante del glucolipido en terapia. | |
| CA2128244A1 (en) | Solid Bodies Containing Active Substances and a Structure Consisting of Hydrophilic Macromolecules, Plus a Method of Producing Such Bodies | |
| EP4146284A1 (en) | Methods to genetically modify cells for delivery of therapeutic proteins | |
| JP2026505800A (ja) | Hsc特異的抗体結合脂質ナノ粒子及びその使用 | |
| Bayard et al. | Increased stability and antiviral activity of 2′‐O‐phosphoglyceryl derivatives of (2′‐5′) oligo (adenylate) Roles of phosphodiesterases and phosphatases in (2′‐5′) oligo (adenylate) catabolism | |
| CA2386536A1 (en) | Methods for treating muscular dystrophy with bone marrow cells | |
| AU2021268253A1 (en) | Methods for targeted insertion of exogenous sequences in cellular genomes | |
| KR20080033501A (ko) | 증식성 질환 또는 염증의 치료를 위한3,11b-시스-디히드로테트라베나진 | |
| FR2553409B1 (fr) | Nouveaux benzenesulfonyl-lactames, leur procede de preparation et leur application comme substance active de compositions pharmaceutiques | |
| DE2930604A1 (de) | Doppelstrangige ribonucleinsaeure, verfahren zu ihrer herstellung und diese enthaltende interferon-induktoren | |
| JP2668214B2 (ja) | Aids治療薬 | |
| US6034112A (en) | Use of flupirtine the prophylaxis and therapy of diseases associated with an impairment of the hematopoetic cell system | |
| Nanba et al. | GMl-gangliosidosis: Abnormalities in biosynthesis and early processing of β-galactosidase in fibroblasts | |
| Siebert et al. | Mitochondrial malic enzyme (EC 1.1. 1.40) in human leukocytes: formal genetics and population genetics | |
| NO20013141L (no) | Arylalkanoylderivater, fremgangsmåter for fremstilling derav, deres anvendelse og farmasöytiske preparater inneholdende disse | |
| IL131436A0 (en) | Compositions for treatment of disorders involving programmed cell death | |
| Kuroda et al. | 3-(4-Carbamoylphenyl)-1-methyltriazene 1-oxide | |
| KR102227398B1 (ko) | 신규 에르고스텐올 글리코시드 유도체의 관절염 치료소재를 포함하는 조성물 | |
| EP1882744A1 (en) | Method for producing an interleukin-2 preparation and the thus obtainable preparation |